



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK ADDED TO CSE COMPOSITE INDEX

Vancouver, British Columbia – (March 25, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF) is pleased to announce that BioMark has been added to the CSE Composite Index (“Index”), effective after the close of trading on Friday, March 20, 2015, as a result of CSE’s quarterly rebalancing of the Index.

Rashid Ahmed, President and CEO of BioMark Diagnostics Inc. states “we are very pleased to have been selected for inclusion in the CSE Composite Index, a primary indicator of market activity for Canadian capital markets. This demonstrates our ongoing dedication to achieve progress for our shareholders. This inclusion also provides our exposure to a broader range of potential investors and improves liquidity for our securities”

About BioMark Diagnostics Inc.

BioMark is developing a proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no

assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.